Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells
|
Homo sapiens
|
0.35
nM
|
|
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
|
None
|
0.35
nM
|
|
Concentration required to inhibit 50% of HIV-1 (human immunodeficiency virus-1) replication
|
Human immunodeficiency virus 1
|
0.35
nM
|
|
Antiviral activity against HIV1 3B in H9 lymphocytes
|
None
|
7.0
nM
|
|
Antiviral activity against HIV1 NL4-3 in MT4 cells
|
None
|
96.0
nM
|
|
Antiviral activity against HIV1 NL4-3 replication in human MT4 cells
|
None
|
96.0
nM
|
|
Antiviral activity against HIV1 PI-R replication in human MT4 cells
|
None
|
430.0
nM
|
|
Antiviral activity against HIV1
|
Human immunodeficiency virus 1
|
1.3
nM
|
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA
|
Human immunodeficiency virus 1
|
11.0
nM
|
|
Antiviral activity against HIV1 assessed as inhibition of release of CA/p24 from CA-SP1/p25 at 37.8 nM by MAGI assay
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV1 infected in human assessed as inhibition of viral replication at 75 mg, po
|
Human immunodeficiency virus 1
|
0.00119
ug.mL-1
|
|
Antiviral activity against HIV1 infected in human assessed as inhibition of viral replication at 150 mg, po
|
Human immunodeficiency virus 1
|
0.00035
ug.mL-1
|
|
Antiviral activity against HIV1 infected in human assessed as inhibition of viral replication at 250 mg, po
|
Human immunodeficiency virus 1
|
0.00055
ug.mL-1
|
|
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA
|
Human herpesvirus 4
|
396.0
molar ratio
|
|
Cytotoxicity against mock-infected human H9 cells
|
Homo sapiens
|
0.35
nM
|
|
Antiviral activity against HIV
|
Human immunodeficiency virus
|
0.35
nM
|
|
Antiviral activity against HIV1 NL4-3 infected in human TZM-b1 cells assessed as reduction in luciferase activity after 2 days by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
130.0
nM
|
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA
|
Human immunodeficiency virus 1
|
1.3
nM
|
|
Cytotoxicity against human H9 cells after 4 days by coulter counter
|
Homo sapiens
|
0.35
nM
|
|
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay
|
Human immunodeficiency virus 1
|
96.0
nM
|
|
Antiviral activity against Human immunodeficiency virus 1 LAI infected in human MT-2 cells by XTT-assay
|
Human immunodeficiency virus 1
|
34.0
nM
|
|
Antiviral activity against Human immunodeficiency virus 1 NL4-3 infected in MT4 lymphocytes assessed as p24 antigen level by ELISA
|
Human immunodeficiency virus 1
|
82.0
nM
|
|
Antiviral activity against HIV1 clinical isolates
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
|
Human immunodeficiency virus 1
|
9.0
nM
|
|
Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
|
Human immunodeficiency virus 1
|
290.0
nM
|
|
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days
|
Human immunodeficiency virus 1
|
0.005
nM
|
|
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days
|
Human immunodeficiency virus 1
|
0.05
nM
|
|
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days
|
Human immunodeficiency virus 1
|
0.5
nM
|
|
Antiviral activity against drug-resistant HIV1 isolate
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Antiviral activity against HIV1
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as reduction of viral p24 level cells by fluorescence assay relative to wild type HIV1 NL4-3 after 4 days by ELISA
|
Human immunodeficiency virus 1
|
76.0
nM
|
|
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA
|
Human immunodeficiency virus 1
|
87.0
nM
|
|
Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
0.35
nM
|
|
Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
0.2999
nM
|
|
Antiviral activity against 0.001 MOI wild type Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication measured 4 days post infection by ELISA
|
Human immunodeficiency virus 1
|
76.0
nM
|
|
Antiviral activity against HIV infected in H9 cells
|
Human immunodeficiency virus
|
0.35
nM
|
|
Antiviral activity against HIV1 NL4.3 infected in MAGIC-5B cells after 48 hrs by beta-galactosidase reporter gene assay
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
Chemopreventive activity in human Raji cells assessed as molar ratio of compound required to inhibit 50% of control of inhibition of TPA-induced EBV-early antigen activation after 48 hrs by immunofluorescence analysis
|
Human herpesvirus 4
|
396.0
molar ratio
|
|
Antiviral activity against HIV1 NL4.3-Ren infected in human MT2 cells assessed as inhibition of viral growth at 10 uM measured 48 hrs post infection by luminometry
|
Human immunodeficiency virus 1
|
50.0
%
|
|
Antiviral activity against HIV1 NL4.3-Ren infected in human MT2 cells assessed as inhibition of viral growth measured 48 hrs post infection by luminometry
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed inhibition of viral replication measured on day 4 postinfection by ELISA
|
Human immunodeficiency virus 1
|
75.0
nM
|
|
Antiviral activity against wild type HIV1 NLRepRlucP373S infected in human MT2 cells after 4 to 5 days by luciferase report gene based multiple cycle drug susceptibility assay
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Antiviral activity against wild type HIV1 NLRepRlucP373S infected in human MT2 cells after 4 to 5 days in presence of 15 mg/ml HSA by luciferase report gene based multiple cycle drug susceptibility assay
|
Human immunodeficiency virus 1
|
974.0
nM
|
|
Antiviral activity against HIV1 containing gag V370A mutant infected in human MT2 cells after 4 to 5 days by luciferase report gene based multiple cycle drug susceptibility assay
|
Human immunodeficiency virus 1
|
553.0
nM
|
|
Antiviral activity against HIV1 infected in human H9 cells
|
Human immunodeficiency virus 1
|
0.35
nM
|
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay in presence of human serum albumin
|
Human immunodeficiency virus 1
|
974.0
nM
|
|
Antiviral activity against wild type HIV1 NL4-3 habouring Gag protein V370A mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
553.0
nM
|
|
Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein T371A mutant infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
Antiviral activity against wild type BVM-resistant HIV1 NL4-3 habouring Gag protein delta T371 infected in human MT2 cells after 4 to 5 days by dual-luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
77.0
nM
|
|
Binding affinity to gag polyprotein in wild type HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Binding affinity to gag polyprotein V370A mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay
|
Human immunodeficiency virus 1
|
552.0
nM
|
|
Binding affinity to gag polyprotein V3621 mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay
|
Human immunodeficiency virus 1
|
74.0
nM
|
|
Binding affinity to gag polyprotein Q369H mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay
|
Human immunodeficiency virus 1
|
7.0
nM
|
|
Binding affinity to gag polyprotein V371A deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
Binding affinity to gag polyprotein T371 deletion mutant in HIV1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral maturation after 4 to 5 days in presence of 10% fetal bovine serum by dual-luciferase reporter assay
|
Human immunodeficiency virus 1
|
77.0
nM
|
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA
|
Human immunodeficiency virus 1
|
65.0
nM
|
|
Inhibition of wild type HIV-1 clade B NL4-3 Gag polyprotein SP1 infected in human MT4 cells
|
Human immunodeficiency virus 1
|
270.0
nM
|
|
Inhibition of bevirimat-resistant HIV1 clade B NL4-3 CA-SP1 Q369H mutant infected in human MT4 cells
|
Human immunodeficiency virus 1
|
383.0
nM
|
|
Inhibition of bevirimat-resistant HIV1 clade B NL4-3 CA-SP1 T371A mutant infected in human MT4 cells
|
Human immunodeficiency virus 1
|
252.0
nM
|
|
Antiviral activity against Human immunodeficiency virus assessed as reduction in maturation
|
Human immunodeficiency virus
|
10.3
nM
|
|
Binding affinity to CA-SP1 P373S mutant in HIV-1 subtype B NL4-3 infected in human MT2 cells assessed as inhibition of viral maturation by measuring virus yields after 4 to 5 days in presence of 10% FBS by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Binding affinity to CA-SP1 P373S mutant in HIV-1 subtype B NL4-3 infected in human MT2 cells assessed as inhibition of viral maturation by measuring virus yields after 4 to 5 days in presence of 10% FBS/15 mg/ml HSA by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
970.0
nM
|
|
Binding affinity to CA-SP1 P373S/V370A double mutant in HIV-1 subtype B NL4-3 infected in human MT2 cells assessed as inhibition of viral maturation by measuring virus yield after 4 to 5 days in presence of 10% FBS by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
552.0
nM
|
|
Binding affinity to CA-SP1 P373S/T371A double mutant in HIV-1 subtype B NL4-3 infected in human MT2 cells assessed as inhibition of viral maturation by measuring virus yield after 4 to 5 days in presence of 10% FBS by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
10.4
nM
|
|
Binding affinity to CA-SP1 P373S/V362I double mutant in HIV-1 subtype B NL4-3 infected in human MT2 cells assessed as inhibition of viral maturation by measuring virus yield after 4 to 5 days in presence of 10% FBS by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
74.0
nM
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
15.36
%
|
|
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
26.0
nM
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
10.87
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.13
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.13
%
|
|
Binding affinity to wild type HIV-1 NL4-3 CA-SP1 cleavage site of Gag-Pol protein assessed as inhibition of HIV-1 maturation
|
Human immunodeficiency virus 1
|
9.0
nM
|
|
Binding affinity to HIV-1 CA-SP1 cleavage site of Gag-Pol protein harboring V370A mutant assessed as inhibition of HIV-1 maturation
|
Human immunodeficiency virus 1
|
553.0
nM
|
|
Binding affinity to wild type HIV-1 NL4-3 CA-SP1 cleavage site of Gag-Pol protein assessed as inhibition of HIV-1 maturation in presence of human serum albumin
|
Human immunodeficiency virus 1
|
974.0
nM
|
|
Binding affinity to HIV-1 CA-SP1 cleavage site of Gag-Pol protein harboring V362I mutant assessed as inhibition of HIV-1 maturation
|
Human immunodeficiency virus 1
|
74.0
nM
|
|
Binding affinity to HIV-1 CA-SP1 cleavage site of Gag-Pol protein harboring G369H mutant assessed as inhibition of HIV-1 maturation
|
Human immunodeficiency virus 1
|
8.0
nM
|
|
Binding affinity to HIV-1 CA-SP1 cleavage site of Gag-Pol protein harboring V370M mutant assessed as inhibition of HIV-1 maturation
|
Human immunodeficiency virus 1
|
111.0
nM
|
|
Binding affinity to HIV-1 CA-SP1 cleavage site of Gag-Pol protein harboring Thr371Ala mutant assessed as inhibition of HIV-1 maturation
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Binding affinity to HIV-1 CA-SP1 cleavage site of Gag-Pol protein harboring deltaThr371 mutant assessed as inhibition of HIV-1 maturation
|
Human immunodeficiency virus 1
|
77.0
nM
|
|
Antiviral activity against wild type HIV-1 NL4-3 infected in MT-2 cells assessed as inhibition of viral replication in presence of 10% of fetal bovine serum by luciferase reporter gene based multicycle replication assay
|
Human immunodeficiency virus 1
|
10.0
nM
|
|
Antiviral activity against wild type HIV-1 NL4-3 harbouring Gag V370A mutant infected in MT-2 cells assessed as inhibition of viral replication in presence of 10% of fetal bovine serum by luciferase reporter gene based multicycle replication assay
|
Human immunodeficiency virus 1
|
552.0
nM
|
|
Antiviral activity against HIV 1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication and measured on day 3 post infection by Nano-glo luciferase reporter assay
|
Homo sapiens
|
21.0
nM
|
|
Antiviral activity against HIV-1 NL4-3 infected in human MT4 cells assessed as reduction in p24 gag protein incubated for 4 days by ELISA
|
Human immunodeficiency virus 1
|
64.57
nM
|
|
Antiviral activity against HIV-1 NL4-3 infected in human MT4 cells assessed as reduction in p24 gag protein incubated for 4 days by ELISA
|
Human immunodeficiency virus 1
|
65.0
nM
|
|